Lau SCM, Ou SI. And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR
Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib,
Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of
EGFR+ NSCLC. J Thorac Oncol 2022;17:1144-1154.
PMID: 36192074